Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune®

NCT00850603 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

170

Enrollment

INDUSTRY

Sponsor class

Conditions

Meningococcal Infections
Meningitis

Interventions

BIOLOGICAL: Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined
BIOLOGICAL: Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined
BIOLOGICAL: Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined
BIOLOGICAL: Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined
BIOLOGICAL: Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined

Sponsor

Sanofi Pasteur, a Sanofi Company